These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28887220)

  • 1. Enhanced glioma therapy by synergistic inhibition of autophagy and tyrosine kinase activity.
    Wang X; Qiu Y; Yu Q; Li H; Chen X; Li M; Long Y; Liu Y; Lu L; Tang J; Zhang Z; He Q
    Int J Pharm; 2018 Jan; 536(1):1-10. PubMed ID: 28887220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significantly enhanced tumor cellular and lysosomal hydroxychloroquine delivery by smart liposomes for optimal autophagy inhibition and improved antitumor efficiency with liposomal doxorubicin.
    Wang Y; Shi K; Zhang L; Hu G; Wan J; Tang J; Yin S; Duan J; Qin M; Wang N; Xie D; Gao X; Gao H; Zhang Z; He Q
    Autophagy; 2016 Jun; 12(6):949-62. PubMed ID: 27123811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways.
    Yin S; Xia C; Wang Y; Wan D; Rao J; Tang X; Wei J; Wang X; Li M; Zhang Z; Liu J; He Q
    J Control Release; 2018 Oct; 288():148-160. PubMed ID: 30099017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma.
    Shen J; Zheng H; Ruan J; Fang W; Li A; Tian G; Niu X; Luo S; Zhao P
    Br J Cancer; 2013 Jul; 109(1):164-71. PubMed ID: 23799852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomes Combined an Integrin αvβ3-Specific Vector with pH-Responsible Cell-Penetrating Property for Highly Effective Antiglioma Therapy through the Blood-Brain Barrier.
    Shi K; Long Y; Xu C; Wang Y; Qiu Y; Yu Q; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
    ACS Appl Mater Interfaces; 2015 Sep; 7(38):21442-54. PubMed ID: 26371468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic cytotoxicity and co-autophagy inhibition in pancreatic tumor cells and cancer-associated fibroblasts by dual functional peptide-modified liposomes.
    Chen X; Yu Q; Liu Y; Sheng Q; Shi K; Wang Y; Li M; Zhang Z; He Q
    Acta Biomater; 2019 Nov; 99():339-349. PubMed ID: 31499197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.
    Sandström M; Johansson M; Andersson U; Bergh A; Bergenheim AT; Henriksson R
    Br J Cancer; 2004 Sep; 91(6):1174-80. PubMed ID: 15305185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
    Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
    Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
    McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
    Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel antitumour strategy using bidirectional autophagic vesicles accumulation via initiative induction and the terminal restraint of autophagic flux.
    Wang Y; Tai X; Zhang L; Liu Y; Gao H; Chen J; Shi K; Zhang Q; Zhang Z; He Q
    J Control Release; 2015 Feb; 199():17-28. PubMed ID: 25499918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
    Ciardiello F; Caputo R; Damiano V; Caputo R; Troiani T; Vitagliano D; Carlomagno F; Veneziani BM; Fontanini G; Bianco AR; Tortora G
    Clin Cancer Res; 2003 Apr; 9(4):1546-56. PubMed ID: 12684431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined integrin α
    Qi N; Zhang S; Zhou X; Duan W; Gao D; Feng J; Li A
    J Nanobiotechnology; 2021 Dec; 19(1):446. PubMed ID: 34949198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
    Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
    J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
    Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F
    J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
    Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
    Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Receptor Recognizing Cell Penetrating Peptide for Selective Targeting, Efficient Intratumoral Diffusion and Synthesized Anti-Glioma Therapy.
    Liu Y; Mei L; Xu C; Yu Q; Shi K; Zhang L; Wang Y; Zhang Q; Gao H; Zhang Z; He Q
    Theranostics; 2016; 6(2):177-91. PubMed ID: 26877777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of ibrutinib and hydroxychloroquine by albumin nanoparticles for enhanced chemotherapy of glioma.
    Yang Z; Du Y; Lei L; Xia X; Wang X; Tong F; Li Y; Gao H
    Int J Pharm; 2023 Jan; 630():122436. PubMed ID: 36436742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
    Rich JN; Sathornsumetee S; Keir ST; Kieran MW; Laforme A; Kaipainen A; McLendon RE; Graner MW; Rasheed BK; Wang L; Reardon DA; Ryan AJ; Wheeler C; Dimery I; Bigner DD; Friedman HS
    Clin Cancer Res; 2005 Nov; 11(22):8145-57. PubMed ID: 16299247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomes actively recognizing the glucose transporter GLUT
    Fu Q; Zhao Y; Yang Z; Yue Q; Xiao W; Chen Y; Yang Y; Guo L; Wu Y
    Arch Pharm (Weinheim); 2019 Feb; 352(2):e1800219. PubMed ID: 30609116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.